Divestitures - Narrative (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
May 28, 2021 |
Jun. 30, 2021 |
Jun. 30, 2021 |
Jun. 30, 2020 |
May 21, 2021 |
May 01, 2021 |
|
Divestitures [Line Items] | ||||||
Proceeds from sale of assets | $ 32,500,000 | $ 0 | ||||
Loss on non-cancelable purchase commitment | $ 5,900,000 | |||||
Loss on inventory | 6,600,000 | $ 6,600,000 | $ 0 | |||
Myriad myPath LLC laboratory | ||||||
Divestitures [Line Items] | ||||||
Proceeds from sale of assets | $ 32,500,000 | |||||
Net gain on sale of assets adjusted for transaction fees | $ 31,200,000 | |||||
Held for sale | ||||||
Divestitures [Line Items] | ||||||
Impairment on write down of assets held for sale | $ 0 | |||||
Held for sale | Select operating assets and intellectual property of Myriad Autoimmune business unit | ||||||
Divestitures [Line Items] | ||||||
Cash consideration | $ 150,000,000.0 | |||||
Held for sale | Myriad RBM, Inc. | ||||||
Divestitures [Line Items] | ||||||
Cash consideration | $ 198,000,000.0 | |||||
Aggregate adjustments for working capital, indebtedness, and transaction costs | $ (3,900,000) |